Patents by Inventor Hong Shen

Hong Shen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210371432
    Abstract: The present invention relates to compounds of formula (I), wherein R1 to R6, m and n are I a described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: June 3, 2019
    Publication date: December 2, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: FABIAN DEY, HONG SHEN, HONGTAO XU, HONGYING YUN, GE ZOU, WEI ZHU
  • Patent number: 11190449
    Abstract: Example packet control methods and apparatus are described. One example method includes detecting a packet flow causing a congestion status change. A congestion isolation message is generated and is used to change a priority of a packet in the packet flow. The congestion isolation message includes description information of the packet flow. The congestion isolation message is sent to at least one node.
    Type: Grant
    Filed: February 18, 2020
    Date of Patent: November 30, 2021
    Assignee: Huawei Technologies Co., Ltd.
    Inventors: Li Shen, Hewen Zheng, Hong Zhou, Nongda Hu, Xiang Yu
  • Publication number: 20210364999
    Abstract: A system for analyzing cause of product defect, including: a distributed storage device configured to store production data generated by a factory device; an analysis device including one or more processors configured to perform: acquiring a production record from the production data; the production record includes information of processing devices used during production procedures for producing the products and information of defects occurring, where each product is processed by multiple processing devices, and each processing device participates in only the production procedures of a portion of the products; determining a correlation weight of the processing device to be analyzed corresponding to a defect to be analyzed according to the production record, and determining a correlation between the processing device to be analyzed and the defect to be analyzed according to the correlation weight; a display device configured to display an analysis result of the analysis device.
    Type: Application
    Filed: November 29, 2019
    Publication date: November 25, 2021
    Inventors: Tian LAN, Hong WANG, Dong CHAI, Haohan WU, Guoliang SHEN, Weihe LIU
  • Publication number: 20210355122
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2, R3 and R4 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: September 6, 2018
    Publication date: November 18, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Fabian Dey, Taishan Hu, Haixia Liu, Hong Shen, Zhiwei Zhang, Wei Zhu
  • Patent number: 11174099
    Abstract: A container comprising a threshold assembly. The threshold assembly comprises an outer end plate, a horizontal connecting member and a middle connecting member. The outer end plate comprises a horizontal portion and a vertical portion; the horizontal member connects to a floor of the container; and the middle member connects to the plate and the horizontal member, wherein one end of the middle member extends to the intersection of the horizontal portion and the vertical portion of the plate; an opening and a clamping groove at the other end of the middle member; and an inserting portion at one end of the horizontal member for inserting into the clamping groove through the opening to connect the horizontal member and the middle member. When force is applied to the threshold assembly, gaps among the horizontal and middle members and the plate are sealed, preventing liquids from causing steel corrosion.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: November 16, 2021
    Assignees: China International Marine Containers (Group) Ltd., CIMC R&D CENTER, CIMC Containers Holding Company Ltd., Taicang CIMC Reefer Logistics Equipment Co.
    Inventors: Guohao Huang, Weiting Yang, Zhaoyun Ma, Yugang Shen, Hong Zhang, Cuiqun Guo
  • Patent number: 11168086
    Abstract: The present invention relates to compounds of the formula (I), or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R4 are as described above. The compounds may be useful for the treatment or prophylaxis of hepatitis B virus infection.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: November 9, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Taishan Hu, Xingchun Han, Buyu Kou, Hong Shen, Shixiang Yan, Zhisen Zhang
  • Publication number: 20210340134
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds as antagonist of TLR7 and/or TLR8 and/or TLR9 in the treatment of autoimmune diseases as well as auto-inflammation diseases.
    Type: Application
    Filed: September 6, 2018
    Publication date: November 4, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Zongxing Qiu, Hong Shen, Wei Zhu, Fabian Dey, Ge Zou, Hongtao Xu
  • Publication number: 20210323977
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, R3 and R4 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: August 28, 2018
    Publication date: October 21, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: HAIXIA LIU, GUOLONG WU, WEIXING ZHANG, WEI ZHU, HONG SHEN, FABIAN DEY
  • Publication number: 20210328005
    Abstract: A metal-insulator-metal (MIM) capacitor structure includes a bottom electrode, a first oxide layer adjacent the bottom electrode, and a first high-k dielectric layer over the bottom electrode and the first oxide layer. A middle electrode is over the first high-k dielectric layer and a second oxide layer is adjacent the middle electrode. A second high-k dielectric layer may be over the middle electrode and the second oxide layer, a top electrode may be over the second high-k dielectric layer.
    Type: Application
    Filed: July 2, 2021
    Publication date: October 21, 2021
    Inventors: Hsiang-Ku SHEN, Ming-Hong KAO, Hui-Chi CHEN, Dian-Hau CHEN, Yen-Ming CHEN
  • Publication number: 20210323981
    Abstract: The present invention relates to novel compounds of formula (I), wherein R1, R2, R3, R4, R5 and R6 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: May 20, 2021
    Publication date: October 21, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Hong SHEN, Xuefei TAN, Chengang ZHOU, Mingwei ZHOU, Yimin HU, Houguang SHI, Fabian DEY, Yongqiang LIU, Xiao DING
  • Publication number: 20210317141
    Abstract: The present invention relates to novel compounds of formula (I), wherein R1 to R7 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: June 17, 2021
    Publication date: October 14, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Fabian DEY, Xiao DING, Yimin HU, Yongqiang LIU, Hong SHEN, Honguang SHI, Xuefei TAN, Chengang ZHOU, Mingwei ZHOU
  • Publication number: 20210309658
    Abstract: The present invention relates to novel compounds of formula (I), wherein R1, R2, R3, R4, R5 and R6 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: May 26, 2021
    Publication date: October 7, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Fabian DEY, Yimin HU, Yongqiang LIU, Hong SHEN, Houguang SHI, Xuefei TAN, Shixiang YAN, Weixing ZHANG, Zhiwei ZHANG, Chengang ZHOU, Mingwei ZHOU, Wei ZHU
  • Publication number: 20210309657
    Abstract: The present invention relates to novel compounds of formula (I), wherein R1, R2, R3, R4, R5 and R6 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: May 26, 2021
    Publication date: October 7, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Fabian DEY, Yimin HU, Yongqiang LIU, Hong SHEN, Houguang SHI, Xuefei TAN, Shixiang YAN, Weixing ZHANG, Zhiwei ZHANG, Chengang ZHOU, Mingwei ZHOU, Wei ZHU
  • Patent number: 11140082
    Abstract: This application provides a data transmission method. The method includes: calculating a first duration based on at least one to-be-sent data flow and a first time interval, where the first time interval is a preset value, and different data flows in the at least one to-be-sent data flow have different 5-tuples; and sending a first data flow, where the first data flow belongs to the at least one to-be-sent data flow; where a first set of packets of the first data flow are sent in a first time period, a second set of packets of the first data flow are sent in a second time period following a second time interval, a duration of the first time period and a duration of the second time period are equal to the first duration, and the second time interval is greater than or equal to the first time interval.
    Type: Grant
    Filed: November 29, 2019
    Date of Patent: October 5, 2021
    Assignee: HUAWEI TECHNOLOGIES CO., LTD.
    Inventors: Li Shen, Hong Zhou, Tao Wu
  • Publication number: 20210300924
    Abstract: The present invention relates to a compound of formula (I) wherein R4 is C1-6alkyl, halogen or cyano; R5 is halogen; R2 is 4,5,6,7-tetrahydropyrazolo[3,4-c]pyridinyl which is unsubstituted or substituted by C1-6alkyl or haloC1-6alkyl; 4,5,6,7-tetrahydropyrazolo[4,3-c]pyridinyl which is unsubstituted or substituted one or two times by C1-6alkyl; or 5,6-dihydro-4H-pyrrolo[3,4-c]pyrazolyl; R3 is C1-6alkyl; L is azetidinyl or piperidinyl; or a pharmaceutically acceptable salt thereof, for use as a TLR7, TLR8 and/or TLR9 antagonist for the treatment or prophylaxis of autoimmune diseases, such as e.g. systemic lupus erythematosus or lupus nephritis.
    Type: Application
    Filed: November 7, 2019
    Publication date: September 30, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Haixia LIU, Hong SHEN, Wei ZHU, Fabian DEY, Xiaoqing WANG
  • Publication number: 20210302690
    Abstract: An optical member driving mechanism for connecting an optical member is provided, including a fixed portion and a first adhesive member. The fixed portion includes a first member and a second member, wherein the first member is fixedly connected to the second member via the first adhesive member.
    Type: Application
    Filed: March 26, 2021
    Publication date: September 30, 2021
    Inventors: Hsiang-Chin LIN, Shou-Jen LIU, Guan-Bo WANG, Kai-Po FAN, Chan-Jung HSU, Shao-Chung CHANG, Shih-Wei HUNG, Ming-Chun HSIEH, Wei-Pin CHIN, Sheng-Zong CHEN, Yu-Huai LIAO, Sin-Hong LIN, Wei-Jhe SHEN, Tzu-Yu CHANG, Kun-Shih LIN, Che-Hsiang CHIU, Sin-Jhong SONG
  • Publication number: 20210300947
    Abstract: The present invention relates to compounds of formula (I), ab (I), wherein R1 to R3 and L are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: June 11, 2019
    Publication date: September 30, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: FABIAN DEY, BUYU KOU, HAIXIA LIU, HONG SHEN, XIAOQING WANG, WEIXING ZHANG, ZHISEN ZHANG, ZHIWEI ZHANG, WEI ZHU
  • Patent number: 11114408
    Abstract: Systems and methods for providing 3D wafer assembly with known-good-dies are provided. An example method compiles an index of dies on a semiconductor wafer and removes the defective dies to provide a wafer with dies that are all operational. Defective dies on multiple wafers may be removed in parallel, and resulting wafers with all good dies stacked in 3D wafer assembly. In an implementation, the spaces left by removed defective dies may be filled at least in part with operational dies or with a fill material. Defective dies may be replaced either before or after wafer-to-wafer assembly to eliminate production of defective stacked devices, or the spaces may be left empty. A bottom device wafer may also have its defective dies removed or replaced, resulting in wafer-to-wafer assembly that provides 3D stacks with no defective dies.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: September 7, 2021
    Assignee: Invensas Corporation
    Inventors: Hong Shen, Liang Wang, Guilian Gao
  • Publication number: 20210269451
    Abstract: The present invention relates to compounds of formula (I), a b (I), wherein R1 to R4 and L are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: June 11, 2019
    Publication date: September 2, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: HAIXIA LIU, HONG SHEN, WEI ZHU, TAISHAN HU, ZHISEN ZHANG, ZHIWEI ZHANG, FABIAN DEY, XIAOQING WANG
  • Publication number: 20210261552
    Abstract: Disclosed are a compound (as shown in formula I) as an extracellular signal-regulated kinase (ERK) inhibitor, a pharmaceutical composition thereof, a preparation method therefor, and use thereof in treating ERK-mediated diseases. Said compound plays a role by regulating a plurality of processes such as cell proliferation, apoptosis, migration and angiogenesis.
    Type: Application
    Filed: June 6, 2019
    Publication date: August 26, 2021
    Applicant: Betta Pharmaceuticals Co., LTD
    Inventors: Hao WU, Wei GU, Xiaojing TANG, Wei WANG, Bo ZHAN, Dongjie FENG, Yongxin KE, Zhongyan CHEN, Yifei SHEN, Wenmao WU, Xintao ZHAO, Hong LAN, Jiabing WANG, Lieming DING